Modesto A, Carrère N, Guimbaud R, Rives M, Deutsch É, Quéro L, Créhange G
Département de radiothérapie, institut Claudius-Regaud, Institut universitaire du cancer de Toulouse, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France.
Département de chirurgie digestive, centre hospitalier universitaire de Toulouse-Rangueil, 1, avenue Jean-Poulhès, 31000 Toulouse, France.
Cancer Radiother. 2019 Oct;23(6-7):716-719. doi: 10.1016/j.canrad.2019.06.010. Epub 2019 Aug 14.
Management of resectable esophageal carcinoma is based on a multimodal treatment associating neo-adjuvant chemoradiation before surgery. This therapeutic sequence allows a disease-free survival rate at 2 years around 45% but remains associated with a high post-operative morbidity. In case of definitive chemoradiotherapy, the dose delivered to the macroscopic disease is a controversial topic since decades and the prognosis of patients treated in this setting at the dose of 50Gy remains poor. This article proposes a review of the main published data and the ongoing studies related to the management of these patients.
可切除食管癌的治疗基于术前新辅助放化疗的多模式治疗。这种治疗方案使2年无病生存率约为45%，但术后发病率仍然很高。在根治性放化疗的情况下，几十年来，给予肉眼可见病变的剂量一直是一个有争议的话题，接受50Gy剂量治疗的患者预后仍然很差。本文对已发表的主要数据以及与这些患者管理相关的正在进行的研究进行了综述。
